Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
7 May 24
8-K
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
26 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Termination of a Material Definitive Agreement
12 Feb 24
8-K
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
25 Jan 24
8-K
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
12 Jan 24
8-K
Regulation FD Disclosure
15 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Regulation FD Disclosure
13 Oct 23
8-K
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial
13 Oct 23
8-K
Regulation FD Disclosure
6 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Other Events
7 Jun 23
S-8
Registration of securities for employees
30 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
9 May 23
8-K
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC
18 Apr 23
8-K
Other Events
10 Mar 23
S-8
Registration of securities for employees
1 Mar 23
8-K
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
9 Nov 22
424B5
Prospectus supplement for primary offering
4 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Entry into a Material Definitive Agreement
1 Jun 22
Latest ownership filings
4
Lloyd Mitchell Segal
1 Apr 24
4
Steve Forte
1 Apr 24
4
Michael Zinda
1 Apr 24
4
Maria Koehler
1 Apr 24
4
Steve Forte
27 Mar 24
4
Michael Zinda
27 Mar 24
4
Maria Koehler
27 Mar 24
4
Lloyd Mitchell Segal
27 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
4
Steve Forte
5 Mar 24
4
Michael Zinda
4 Mar 24
4
Lloyd Mitchell Segal
4 Mar 24
4
Maria Koehler
4 Mar 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
4
Maria Koehler
12 Dec 23
4
MARK N LAMPERT
17 Nov 23
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
17 Nov 23
4
MARK N LAMPERT
3 Nov 23
SC 13D
BIOTECHNOLOGY VALUE FUND L P
3 Nov 23
4
CAROL SCHAFER
12 Jun 23
4
ANN D RHOADS
12 Jun 23
4
Briggs Morrison
12 Jun 23
4
Susan Molineaux
12 Jun 23
4
Samarth Kulkarni
12 Jun 23
4
Todd Foley
12 Jun 23
4
Thomas Civik
12 Jun 23
4
David P Bonita
12 Jun 23
3
Susan Molineaux
12 Jun 23
4
Michael Zinda
9 Jun 23
4
Michael Zinda
7 Jun 23
144
Notice of proposed sale of securities
6 Jun 23
144
Notice of proposed sale of securities
10 May 23
SC 13G/A
Redmile Group, LLC
14 Feb 23